

References

- 1.Peters, M. D. J., Godfrey, C. M., Khalil, H., McInerney, P., Parker, D., & Soares, C. B. (2015). Guidance for conducting systematic scoping reviews. *International Journal of Evidence-Based Healthcare*, 13(3), 141-146
- 2.Zu K, Arunachalam A, Hohlbauch A, Silver M, Robert N. Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings. *Immunotherapy*. 2023;15(16):1375-1387. doi:10.2217/imt-2023-0073
- 3.Steffens CC, Elender C, Hutzschenreuter U, et al. Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study. *Lung Cancer*. 2019;130:216-225. doi:10.1016/j.lungcan.2019.02.026
- 4.Cramer-van der Welle CM, Schramel FMNH, van Leeuwen AS, Groen HJM, van de Garde EMW, Santeon SCLC Study Group. Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer. *Eur J Cancer Care (Engl)*. 2020;29(5):e13250. doi:10.1111/ecc.13250
- 5.Barsouk AA, Sussman JH, Yaskolko M, et al. Performance status and tarlatamab outcomes in a large, multi-institution real-world database of 2L+ ES-SCLC. *J Clin Oncol*. 2026;44(16_suppl):e20120. doi:10.1200/JCO.2026.44.16_suppl.e20120
- 6.Bolte FJ, Dougherty SC, Danos AO, et al. Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases. *Clin Lung Cancer*. 2025;26(5):347-353.e1.
- 7.von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol*. 1999;17(2):658-667. doi:10.1200/JCO.1999.17.2.658
- 8.Wespiser M, Gille R, Pérol M. Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer. *Expert Opin Investig Drugs*. 2025;34(6):463-471. doi:10.1080/13543784.2025.2512566
- 9.Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. *N Engl J Med*. 2023;389(22):2063-2075. doi:10.1056/NEJMoa2307980
- 10.Mountzios G, Sun L, Cho BC, et al. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. *N Engl J Med*. 2025;393(4):349-361. doi:10.1056/NEJMoa2502099
- 11.Kuehne N, Hueniken K, Xu M, Shakik S, Vedadi A, Pinto D, Brown MC, Bradbury PA, Shepherd FA, Sacher AG, Leighl NB, Xu W, Lok BH, Liu G, O'Kane GM. Longitudinal assessment of health utility scores, symptoms and toxicities in patients with small cell lung cancer using real world data. *Clin Lung Cancer*. 2022;23(2):e154-e164
- 12.Richards DA, Hussein MA, McCune SL, et al. Symptom Burden in Extensive Disease Small Cell Lung Cancer (ED-SCLC): A prospective, observational study in U.S. community practices. *J Clin Oncol*. 2018;36(30_suppl):196-196. doi:10.1200/JCO.2018.36.30_suppl.196